Compare Novartis AG (NVS) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Williams-Sonoma, Inc. — how do they compare? Novartis AG trades at $139.46 (market cap $262.64B), while Williams-Sonoma, Inc. trades at $228.08 (market cap $26.83B). The key difference: Novartis AG is far larger — about 9.8× Williams-Sonoma, Inc.'s market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | WSM | |
|---|---|---|
Market Cap | $262.64B | $26.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $251.81 |
52-Week Low | $121.80 | $168.64 |
Enterprise Value | $303.97B | $27.33B |
Dividend Yield | 3.44% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Williams-Sonoma (WSM) trades at $227.83, up 0.18% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $2.10 exceeding expectations. Revenue growth of 6.2% in Q2 2026 reflects market share gains in a flat home furnishings industry, supported by a robust net income margin of 14.73% and ROE of 54.96%.
The outlook is positive given raised full-year guidance and analyst consensus price target of $252.62, though near-term risks include tariff pressures on margins and technical resistance near $231. Institutional buying, such as HSBC's 12.1% stake increase in Q2 2026, underscores confidence in continued execution amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
